Will $GILD clear resistance after this 2.36% bounce?
$Gilead Sciences(GILD)$
$Gilead Sciences, Inc.(GILD) Rebounds +2.36%: HIV Drug Catalyst Ignites Rally, Eyes $128 Breakout 📈
Latest Close Data 🔵
Closed at $127.23 on 2026-06-17, up +2.36% (+$2.93). The stock trades ~19.1% below its 52-week high of $157.29.
Core Market Drivers 💊
-
The rally is primarily fueled by positive HIV pipeline news.
-
The FDA accepted Gilead's sNDA for a weekly oral HIV prevention drug (PDUFA date Feb 2027).
-
This follows strong Phase 3 data for its Islatravir/Lenacapavir combo, reinforcing its leadership in HIV treatment and helping the stock recover from recent Trodelvy trial setbacks.
Technical Analysis 📊
-
Volume: Trading volume of 9.38M shares shows active participation (Volume Ratio: 1.19), supporting the upward move.
-
RSI (6): Jumped to 51.25, moving out of oversold territory (<30) and signaling a shift in short-term momentum.
-
MACD: The latest MACD histogram is -0.57, still negative but showing a significant reduction in bearish momentum (converging towards a potential bullish crossover).
Key Price Levels 🎯
-
Primary Support: $123.52 (Recent swing low, must hold).
-
Strong Resistance: $138.41 (Key technical barrier from previous analysis).
-
Immediate Pivot: $128.18 (Today's high; a break above confirms bullish continuation).
Valuation Perspective 💰
Trailing P/E is 17.3x, which is reasonable for a large-cap biopharma. However, the Forward P/E is deeply negative (-156.39), reflecting significant near-term earnings uncertainty, likely tied to R&D investments and pipeline transitions.
Analyst Targets 🎯
Coverage remains bullish. 28 analysts have an average price target of $158.05 (upside of ~24%). Sentiment is positive with 8 Strong Buy, 18 Buy, and 6 Hold ratings.
Weekly Outlook 🔮
Expect consolidation near the $127-$128 zone. A decisive break above $128.18 could target the $130-$132 range. Failure to hold $123.52 support may lead to a retest of the $120 level. The technical picture is improving but needs to clear the immediate pivot.
Risk Disclaimer ⚠️ This analysis is for informational purposes only and not financial advice. Investing involves risks, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research or consult a qualified financial advisor before making any investment decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
